References
- Sherbenou DW, Druker BJ. Applying the discovery of the Philadelphia chromosome. J Clin Invest 2007; 117: 2067–74
- Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–17
- Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, et al. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): Prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia 2003; 17: 1529–37
- Champlin RE, Golde DW. Chronic myelogenous leukemia: Recent advances. Blood 1985; 65: 1039–47
- Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164–72
- Johansson B, Mertens F, Fioretos T, Heim S, Kristoffersson U, Mandahl N, et al. Remarkably long survival of a patient with Ph1-positive chronic myeloid leukemia and 5' bcr rearrangement. Leukemia 1990; 4: 448–9
- Busuttil DP. Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival. Int J Lab Hematol 2008; 30: 68–70